Project Grant RF1NS142703
- This federal Project Grant award of $222,758 from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), is funding research to map the functional roles of different neuron types in the dorsal root ganglia (DRG) and understand their contributions to pain perception in the brain. The primary awardee, the University of North Carolina at Chapel Hill (UNC-CH), will use innovative optogenetic and chemogenetic techniques to selectively...
- This $453,104 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to explore independent ascending spinal pain circuits that transmit pain signals to the brain. The primary focus is on understanding the role of a newly identified subset of spinal projection neurons expressing the GPR83 neuropeptide receptor, in...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $444,125 in funding to Duke University to explore the role of the LRRC55 regulatory protein in pain pathways. The key objectives are to: 1) delineate LRRC55's function in chronic pain behaviors using genetically-modified mice, 2) quantify changes in LRRC55 expression in dorsal root ganglion and spinal cord neurons...
- This $2,249,392 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to validate senescent cells as a target for the treatment of chronic pain in aging. The project aims to rigorously characterize the role of senescent neurons and their senescence-associated secretory phenotype (SASP) in driving dorsal root ganglion hyperexcitability and persistent pain following...
- This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $664,772 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the University of Texas Southwestern Medical Center. The grant supports research to investigate the mechanisms by which the neurotensin receptor 2 (NTSR2) interacts with calcium channels as a potential non-opioid analgesic mechanism for treating chronic pain. The project involves characterizing...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $400,000 Project Grant to Navega Therapeutics, Inc., a San Diego-based biotechnology company, under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The funding will support Navega's research and development efforts to advance novel epigenetic gene therapies targeting the voltage-gated sodium channel NAV1.7 for the treatment of chronic pain. This innovative approach aims to transiently repress NAV1.7...
- This $147,486 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to Carnegie Mellon University supports research to identify and target neural subpopulations in the spinal cord that mediate chronic pain. The project aims to analyze the genomic cis-regulatory elements (CREs) of neural subtypes in the macaque and mouse spinal cord to characterize the genetic markers...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $246,750 to The Trustees of Columbia University in the City of New York, Health Sciences Division, to research the role of the mesocortical glutamatergic pathway in the development and maintenance of chronic neuropathic pain. The project aims to use in vivo imaging,...
- This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
This $4,039,366 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), will support a research project titled "A Fully Humanized Functional Genomic Screen to Identify and Validate Pain Therapeutic Targets" under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279). The project will leverage innovative CRISPR-based screening and human dorsal root ganglion (DRG) transcriptomic data to identify and validate high-quality targets for chronic pain treatment. It will focus on understanding the regulation of key ion channels and receptors, such as Nav1.7, TRPV1, and GP130, that are critical for normal nociceptor function and linked to chronic pain. The research will be conducted by the University of Texas at Dallas, leveraging its expertise in areas like biomedical research, materials science, and advanced data analytics. The award period is from September 1, 2025 to August 31, 2028.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $4.0m | 8/15/25 |